Introduction
Regulated proteolysis by the ubiquitin-proteasome pathway (UPP) has a key role in both intracellular homeostatis and in the execution of a great number of signal-transduction pathways (Hershko and Ciechanover, 1998; Schubert et al., 2000; Conaway et al., 2002; Glickman and Ciechanover, 2002 ). An intact and properly regulated UPP is therefore an essential prerequisite for cell growth, cell viability and many other biological processes (McBride et al., 2003; Goldberg, 2007; Gudmundsdottir et al., 2007; Yi and Ehlers, 2007; van Tijn et al., 2008) . Consequently, deregulation and dysfunctions in the UPP account for severe pathological conditions, such as immune defects, neurodegenerative disorders and cancer (Orlowski and Dees, 2003; Chen and Madura, 2005; Devoy et al., 2005; Mani and Gelmann, 2005; Sun, 2006; Dahlmann, 2007) .
The degradation of proteins once recruited to the UPP is executed by the 26S proteasome (26S-Pr), a large multiprotein complex representing the major site of nonlysosomal proteolysis in the eukaryotic cell (Coux et al., 1996; Baumeister et al., 1998; London et al., 2004) . The 26S-Pr is located both in the cytosol and the nucleus and consists of a dimeric, barrel-shaped catalytical subunitthe 20S proteasome or 20S catalytical particle (20S-CP)-flanked on each site by two cap-like regulatory subunits-termed 19S regulatory particles (19S-RP) (Coux et al., 1996; Baumeister et al., 1998) . The assembly and disassembly of 26S-Pr, its maturation and the expression of more than 30 different proteasomal subunit proteins are tightly regulated processes (London et al., 2004; Murata et al., 2009) controlled by subunit self-processing, by the actions of maturation proteins and certain transcription factors and also by the cellular energy status (Schmidtke et al., 1996; Xie and Varshavsky, 2001; Leggett et al., 2002; Smith et al., 2005; Liu et al., 2006) .
With respect to cancer, more and more evidence accumulates that, beside amplifications in signal-transduction pathways upstream to the UPP, the proteasome activity itself is also elevated in tumor cells (Ren et al., 2000; Wyke et al., 2004; Chen and Madura, 2005) . This finding is in line with the fact that tumor cells are much more sensitive to proteasome inhibitors than normal cells (Adams, 2004) , thus indicating that tumor cells particularly depend on high proteasome activity. Such a condition probably reflects the need of tumor cells to get rid of many immature and irregular proteins that would be otherwise harmful to the cell (Schubert et al., 2000; Goldberg, 2003) , as well as the need for maintaining certain signal-transduction pathways-that is, the IkB/ NF-kB pathway-that protect the tumor cell from apoptosis (Wang et al., 1999; Karin et al., 2002; Zhang et al., 2004) . Accordingly, proteasome inhibition has meanwhile become a valuable and powerful tool in the treatment of certain types of cancer (Almond and Cohen, 2003; Goy et al., 2003; Adams, 2004 ); yet, other tumor entities turned out to be rather resistant to proteasome inhibitors. Nevertheless, recent studies (Chen et al., 2009; Pitts et al., 2009) showed that proteasome inhibition might also be effective for the treatment of colon cancer.
Still, the mechanisms leading to the elevated proteasome activity in tumors are largely unknown, but recent data point to an involvement of the overexpression of proteasomal subunit proteins. For example, tumor samples from breast cancer patients show elevated expression level of certain proteasomal subunits when compared with normal tissue, along with higher proteasome activity (Chen and Madura, 2005) . In melanoma, overexpression of the proteasomal subunit, S10, has been reported, emerging from gene amplification due to a chromosomal translocation (Ren et al., 2000) and accounting for an increased proteasome activity. In a recent study, the 20S-CP protein, PSMB7, was identified to be overexpressed in colon cancer tissue (Rho et al., 2008) .
In yeast, it has been shown that the de novo synthesis of proteasomal proteins is under tight control of the transcription factor, Rpn4, which is itself a UPPcontrolled protein and thus represent a feedback regulator of the 26S-Pr gene expression (Xie and Varshavsky, 2001; London et al., 2004) . However, the mammalian homolog of Rpn4 has not been identified so far. Instead, other transcription factors seem to be involved, in particular, the antioxidative transcription factor, nuclear factor E2-related factor 2 (Nrf2) (Kwak et al., 2003; Hu et al., 2006; Kwak and Kensler, 2006; Arlt et al., 2007) , which is also a target protein of 26S-Pr. Nrf2 is mainly involved in cellular phase II responses to oxidative stress and is under the control of the Keap1 regulatory protein in a redox-dependent manner. In response to oxidative stress (reactive oxygen species (ROS) and glutathione (GSH) depletion) and electrophilic insults (that is, by antioxidants such as tert-butylhydroquinone (tBHQ) or sulforaphane) (Ishii et al., 2000; Huang et al., 2002; Wakabayashi et al., 2004; Cho et al., 2005) , the E3-ligase adaptor, Keap1, dissociates from Nrf2, thereby releasing it from polyubiquitination and proteasomal degradation (Itoh et al., 1999) . Nrf2 then enters the nucleus and induces antioxidant target genes and also a number of proteasomal proteins (Hu et al., 2006) . Along with others, we have shown that many of the proteasomal subunit genes possess an antioxidant response element in their promoter, which is under the control of Nrf2 (Kwak et al., 2003; Kwak and Kensler, 2006; Arlt et al., 2007) . In tumors, a link between Nrf2 signalling and proteasomal dysfunction has not been established yet, but it is conceivable that stress-adapted tumor cells constitutively activate Nrf2.
In this study we screened colon tumor samples for proteasome activity and proteasome subunit protein expression on the one hand and for Nrf2 activity on the other hand. Particular attention was paid to the 19S-RP protein, S5a/PSMD4, and the 20S-CP protein, a-5/ PSMA5, expected to be involved in the exaggerated proteasome activity in cancer (Murata et al., 2009) . Using human colon cancer cell lines and a human colonic epithelial cell line, the observed link between Nrf2 activation and proteasome activity was further verified in vitro.
Results
Increased proteasome activity in colon cancer tissue Cell lysates of frozen tissue specimens from 21 colon cancer patients were analysed for proteasome activity using the N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosyl-7-amido-4-methylcumarin substrate assay. As shown by the proteasome-specific (MG132-inhibitable) release of the fluorescent cleavage product, AMC, tumor tissues showed significantly (Po0.005) increased levels (mean±s.d.: 9700±4120, specific OD/mg protein) of proteasome activity as compared with normal colon tissue (mean ± s.d.: 5250 ± 2080, specific OD/mg protein) from the same patient ( Figure 1a) . In 17 out of 21 tissue samples (>80%), higher proteasome activity was Figure 1 Screening of matched tumoral and normal tissue from colon cancer patients for proteasome activity, S5a and a-5 protein level and nuclear factor E2-related factor 2 (Nrf2) levels. (a) Tissue homogenates were adjusted for equal protein concentration and submitted to a proteasome assay using the N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosyl-7-amido-4-methylcumarin (Suc-LLVY-AMC) substrate. Proteasome specificity was determined by the difference of AMC formation in the absence and presence of 5 mg/ml MG132 and the results are expressed as specific AMC formation (fluorescence units)/mg protein. In the upper panel, results of individual samples from 21 patients (p1-p21) are shown along with tumor characteristics indicated below (according to Sobin and Wittekind, 2002) : T, tumor status; N, node status; M, metastatic status; G, grading. The lower panel shows the mean ± s.d. (n ¼ 21), *Po0.005. (b, c) Whole cell lysates or nuclear extracts were prepared from frozen tissue samples and adjusted for equal protein concentration. (b) S5a and a-5 protein level in whole cell lysates were analysed by western blotting using actin as control. (c) Nrf2 protein level in nuclear extracts from 21 patients were analysed by western blotting (upper panel) using Hsp90 as control, and antioxidant response element (ARE)-binding activity in nuclear extracts from 11 patients was determined using gel shift assay (lower panel); c 1,2 ¼ control: Colo320 ± hemagglutinin (HA)-Nrf2.
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A Arlt et al detected in the tumoral tissue than in the surrounding normal tissue. This included nine samples, in which the proteasome-specific AMC formation of the tumor was more than twofold higher in comparison with the normal tissue, and seven samples in which AMC formation was 1.5-to 2-fold higher. The western blot analysis of total cell lysates prepared from tumor tissues revealed that S5a and a-5-representing 19S and 20S subunit proteins, respectively-are expressed at higher levels in the tumor when compared with normal tissue. With the exception of three cases, all colon cancer samples showed such an increase in S5a and a-5 protein levels ( Figure 1b ).
Elevated nuclear localization of nuclear factor E2-related factor 2 (Nrf2) in colon cancer tissue Addressing the question of whether the increased proteasome activity and expression of S5a and a-5 relate to higher activation of Nrf2, nuclear extracts from colon cancer tissues were submitted to Nrf2 western blot analysis. As shown in Figure 1c (upper panel), nuclear levels of Nrf2 were elevated in tumoral tissue as compared with normal tissue. In >50% (n ¼ 11) of all cases, the level of Nrf2 was strongly increased. In six cases the level of Nrf2 was slightly higher and in two cases Nrf2 levels were almost equal, respectively. Two cases showed a slightly lower Nrf2 level in the tumoral tissue.
In addition, 12 matched tissue samples of sufficient amount of nuclear protein from both normal and tumor tissue were also screened for nuclear Nrf2 activity using gel shift assay ( Figure 1c , lower panel). Using a radiolabelled consensus antioxidant response element oligonucleotide as probe, elevated levels of Nrf2-DNA complexes were detected in 10 tumor samples as compared with normal tissue. This pattern (10 out of 12) strongly matches the corresponding results from western blot analysis, thus confirming higher Nrf2 activity in these cancer cells.
Collectively, the majority of the tumor samples showing higher proteasome activity and S5a and a-5 expression fairly matches the increased status of nuclear Nrf2 (Supplementary Figure 1) . There was a considerable correlation (r 2 ¼ 0.70 and 0.63, respectively) between proteasome activity (see Figure 1a ) and S5a or Nrf2 protein level (upon densitometric evaluation of western blot analyses, Figures 1b and c) and also between NRF2 and S5a level (r 2 ¼ 0.77). Similar correlation was seen between a-5 level and proteasome activity and Nrf2, respectively (data not shown).
Immunostaining for S5a and nuclear factor E2-related factor 2 (Nrf2) in tumor tissue sections In order to confirm that the higher expression levels of Nrf2 and S5a in the tumoral tissue derive from the adenocarcinoma cells, rather than from leukocyte infiltrations, immunohistochemistry analysis of frozen tissue sections was performed. As shown in Figure 2 , strong staining of tumors for S5a and Nrf2 was detectable, and those tumoral areas immunopositive for S5a and Nrf2 were also positive for cytokeratin-20, indicating the epithelial origin of the bulk of S5a and Nrf2 immunoreactivity. Moreover, S5a and Nrf2 staining in tumor cells was detectable in both the nucleus and the cytoplasm (Figure 2b ). This staining pattern indicates that the rise of Nrf2 activity and the expression of proteasomal proteins mainly occur in the transformed colonic epithelium.
Induction and overexpression of nuclear factor E2-related factor 2 (Nrf2) enhances proteasome activity in colon cancer cell lines and colon epithelial cells In order to strengthen the hypothesis that Nrf2 activation relates to proteasome activity, the colorectal cancer cell lines, Colo320 and LoVo, were treated with the well-established Nrf2 inducer, tBHQ (50 mM). At 4 and 8 h after tBHQ administration, the nuclear levels of Nrf2 and antioxidant response element/protein complexes increased in both cell lines (Figure 3a) , indicating Nrf2 activation. A similar effect was seen when stimulating the established human colonic epithelial cell line, NCM460, with tBHQ. Again, the Nrf2 activity was elevated within 4-8 h of tBHQ treatment, as shown by western blot and gel shift assay ( Figure 3a) .
After 24 h of tBHQ treatment, a significant increase in AMC formation was observed in all three cell lines (Figure 3b ), indicating elevated proteasome activities. The proteasome activity was raised by 72, 67 and 130% in LoVo, Colo320, and NCM460 cells, respectively, when compared with untreated cells. Moreover, transient transfection of hemagglutinin (HA)-tagged Nrf2 complementary DNA into LoVo, Colo320 and NCM460 cellsas verified by western blot (Figure 4b )-also led to an increase in proteasome activity. As shown by proteasome assay (Figure 3c ), the proteasome activity was raised by 76, 51 and 70% in Nrf2 overexpressing LoVo, Colo320 and NCM460 cells, respectively, as compared with the corresponding mock transfected controls.
The Nrf2 induction and overexpression in colon cancer cell lines and colon epithelial cells increases the expression of S5a and a-5 To confirm an induction of S5a and a-5 expression upon Nrf2 activation, real-time PCR and western blot analysis ( Figure 4a , upper and lower panels, respectively) were performed. These analyses revealed an increase in S5a and a-5 mRNA and protein level in LoVo, Colo320 or NCM460 cells, respectively, after tBHQ treatment (50 mM) for 4, 8 and 24 h. At 48 h after transient transfection of HA-Nrf2, increased protein level of S5a and a-5 in LoVo, Colo320 and NCM460 cells could also be noted, when compared with the corresponding mock transfected controls (Figure 4b ).
Silencing of nuclear factor E2-related factor 2 (Nrf2) expression in colon cancer cell lines and colon epithelial cells reduces proteasome activity To further validate the involvement of Nrf2 in the induction of proteasome activity, LoVo and Colo320, as well as NCM460 cells, were treated with Nrf2 small interfering RNA (siRNA) or control siRNA for 48 h, followed by administration of tBHQ. As shown by western blot analysis, the tBHQ-dependent increase in S5a and a-5 protein level was attenuated in Nrf2 siRNA-treated LoVo, The same panel of immunostainings of tumoral tisssue for S5a, Nrf2 and CK20 was compared at higher magnification ( Â 250), and controls were chosen as described above.
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LoVo, Colo320 and NCM460 cells, respectively, compared with control siRNA-treated cells.
The silencing of S5a and a-5 expression abrogates tBHQ-induced proteasome activity in colon cancer cell lines and colon epithelial cells To assess whether the tBHQ-dependent and Nrf2-mediated induction of proteasome activity involves S5a and a-5 expression, both proteins were silenced by siRNA ( Figure 5a ). As shown by proteasome assay (Figure 5b ), LoVo, Colo320 and NCM460 cells show decreased levels of tBHQ-induced proteasome activity when treated with S5a and a-5 siRNA. Although this decrease was moderate upon silencing of S5a in LoVo and Colo320 cells (by 20 and 17% of the tBHQ-induced AMC formation in cells treated with control siRNA, respectively), this effect was more pronounced in S5a siRNAtreated NCM460 cells (by 35% of the tBHQ-induced AMC formation in control cells) and in all cell lines when treated with a-5 siRNA (by 49, 42 and 41% of the tBHQinduced AMC formation in control cells, respectively).
Nrf2-induced S5a and a-5 expression in colon epithelial cells confers protection from tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis To address whether Nrf2-induced S5a and a-5 expression confers antiapoptotic protection, NCM460 cells were treated with 50 mM tBHQ for 24 h, followed by apoptosis induction using 0.1 mg/ml TRAIL. Caspase-3/7 assays ( Figure 6a ) and annexinV/propidium iodide assays (Figure 6b ) revealed that tBHQ pretreatment significantly suppressed caspase-3/7 activation ( Figure 6a , left panel) and the increase in annexinV staining (Figure 6b , left panel) after TRAIL treatment. Similarly, NCM460 cells showed lower TRAIL-induced caspase-3/7 activity and annexinV staining when overexpressing Nrf2 (Figures 6a and b, right panels) , and TRAIL-induced cleavage of caspase-3, as detected by western blotting, was less pronounced in NCM460 cells if treated with tBHQ or overexpressing Nrf2 (Figure 6c) . Conversely, tBHQ-treated NCM460 cells showed higher caspase-3/7 activity and annexinV staining, both in the absence and presence of TRAIL, when subjected to Nrf2, a-5 or S5a siRNA transfection (Figures 6d and e) . Expectedly, the proteasome inhibitor, Mg132, greatly increased the sensitivity toward TRAIL in NCM460 cells (Supplementary Figure 3) . Moreover, siRNA-mediated knockdown of Nrf2, a-5 or S5a enhanced TRAILinduced cleavage of caspase-3 in tBHQ-treated NCM460 cells (Figure 6f ). Together, these data point to a protecting effect of Nrf2 against TRAIL-induced apoptosis, which depends on S5a and a-5 expression.
TRAIL resistance through Nrf2-induced S5a and a-5 expression in colon epithelial cells involves an increased NF-kB activation and expression of antiapoptotic target genes. From the observation that Nrf2-induced proteasome activity contributes to the resistance against TRAIL and as TRAIL has been shown inducing NF-kB through the canonical pathway (Trauzold et al., 2001; Ehrhardt et al., 2003) , we looked whether an altered NF-kB response relates to this effect. Interestingly, NCM460 cells showed a marked turnover of IkBa and an increased NF-kB activity in response to TRAIL treatment when overexpressing Nrf2 (Figure 7a) . Moreover, expression of the antiapoptotic NF-kB target gene, cIAP1, was induced by TRAIL on mRNA and protein level more strongly in NCM460 cells transfected with Nrf2 (Figures 7b and c) than in mock transfected cells. This effect was weaker with other NF-kB targets, such as Mcl1 and cIAP2. Upon tBHQ preincubation, the TRAIL induced NF-kB activation in NCM460 cells (Figure 7d) and the increased expression of cIAP1-and to a lesser extent of cIAP2 and Mcl1-were diminished by Nrf2-, S5a-and a-5-siRNA treatment (Figures 7e and f) . 
Discussion
In cancer, the UPP is affected in multiple ways, leading to an increased turnover rate of signalling molecules involved in the regulation of cell growth and apoptosis. As a hallmark of this condition, the activity of the proteasome itself is increased in tumor cells, an event that may result from overexpression of certain protein components of the 26S-Pr (Ren et al., 2000; Chen and Madura, 2005; Rho et al., 2008) . For the first time, this study shows a relation between an increased activation of Nrf2 in cancer and the overexpression of proteasomal subunit proteins-that is, S5a and a-5-along with an elevated proteasome activity. Our study emphasizes these two proteasomal proteins as being likely involved in the exaggerated proteasome activity in colon cancer. While a-5 is an integral part of the 20S-CP and is required for adenosine triphosphatase-mediated threading of the substrate into the 20S-CP, the 19S-RP protein S5a has a particular role in the assembly of the 26S-Pr as it connects the lid and base during 19S-RP biosynthesis (Murata et al., 2009) . Moreover, s5a is responsible for the recruitment of ubiquitinated substrates to the 26S-Pr (Elsasser et al., 2004; Kang et al., 2007) . Thus, the finding that S5a-similar to a-5-is indispensable, not only from the proteasome activity in NCM460 or Colo320 cells, but also from the antiapoptotic protection of these cells, underscores its functional importance for both the UPP and UPP-mediated survival. Accordingly, a previous study identified S5a as an early target in the execution of apoptotis (Sun et al., 2004) . In addition to the analysis of tumor samples from colon cancer patients, cell culture-based experiments, using Colo320 and LoVo colorectal cancer cells and the colonic epithelial cell line NCM460, confirmed Nrf2-dependent induction of both proteasomal gene expression and proteasome activity. After exposure of these cells to electrophilic stress by administration of tBHQ, Nrf2 is released from its repression by Keap1 (Itoh et al., 1999) , followed by an elevated mRNA and protein level of S5a and a-5 as well as by an increase in proteasome activity. Thus, both electrophilic and oxidative stress-conditions quite common during tumorigenesis-lead to persistent Nrf2 activation and thereby to an exaggerated proteasome formation and activation. Under such stress conditions, that is, during inflammation, the expression of proteasome proteins might be enhanced in a Nrf2-dependent manner, accounting for increased proteasome activity and UPP-mediated survival and growth of colon cancer cells. In line with this notion, very recent studies revealed that proteasome inhibition or knockdown of certain proteasomal subunit proteins impair the growth and survival of colorectal cancer cells (Chen et al., 2009; Pitts et al., 2009) . Nuclear factor E2-related factor 2 (Nrf2)-induced S5a and a-5 expression in colon epithelial cells confers protection from tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. NCM460 cells (a-c) were left without tert-butylhydroquinone (tBHQ) or were treated with 50 mM tBHQ for 24 h, or were transfected with the empty vector or with the hemagglutinin (HA)-Nrf2 expression vector, followed by treatment with 0.1 mg/ml TRAIL for 16 h, or not. Apoptosis was determined by the caspase-3/7 assay (a) or the annexinV assay (b) and data are expressed as mean ± s.d. from four independent experiments; *Po0.05 versus untreated and mock transfected cells, respectively. (c) Caspase-3 cleavage in NCM460 cells was analysed by western blotting and representative results out of two independent experiments are shown. (d-f) Upon transfection with control-, Nrf2-, a-5-or S5a-small interfering RNA (siRNA) for 48 h and subsequent treatment with 50 mM tBHQ for 24 h, NCM460 cells were treated with 0.1 mg/ml TRAIL for 16 h, or not. Apoptosis was determined using the caspase-3/7 assay (d) or the annexinV assay (e) and data are expressed as mean ± s.d. from four independent experiments; *Po0.05 versus control siRNA. (f) Caspase-3 cleavage in NCM460 cells was analysed by western blotting and representative results out of two independent experiments are shown.
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The observation that Nrf2, proteasomal gene expression and proteasomal activity are inducible in nonmalignant colonic epithelial cells by electrophilic insults (such as by tBHQ treatment) indicates that this condition might occur already in the intestinal epithelium during electrophilic and oxidative stress. As long as the Nrf2-dependent induction of proteasome activity does not confer growth advantages, the otherwise Figure 7 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance through nuclear factor E2-related factor 2 (Nrf2)-induced S5a and a-5 expression in colon epithelial cells involves an increased nuclear factor (NF)-kB activation and expression of antiapoptotic target genes. NCM460 cells (a) were transfected with the empty vector or with the hemagglutinin (HA)-Nrf2 expression vector, followed by treatment with 0.1 mg/ml TRAIL for 1 h, or not. Cell lysates were analysed using western blotting for IkBa and tubulin (left panel) and nuclear extracts were submitted to NF-kB gel shift assay (right panel). The specificity of the NF-kB band was verified (arrow heads) by anti-p50 and anti-p65 supershifts. (b, c) Mock or HA-Nrf2 transfected NCM460 cells were left untreated or were treated with 0.1 mg/ml TRAIL, and the expression of cIAP1, cIAP2, and Mcl1 was analysed by (b) real-time PCR or by (c) western blotting using tubulin as control. (d) Upon transfection with control-, Nrf2-, a-5-or S5a-small interfering RNA (siRNA) for 40 h and subsequent treatment with 50 mM tert-butyl-hydroquinone (tBHQ) for 24 h, NCM460 cells were treated with 0.1 mg/ml TRAIL, or not. Cell lysates were analysed using western blotting for Nrf2, S5a, a-5, IkBa and tubulin (left panel) and nuclear extracts were submitted to NF-kB gel shift assay (right panel). (e, f) The siRNA-transfected and tBHQ-pretreated NCM460 cells were left untreated or were treated with 0.1 mg/ml TRAIL and the expression of cIAP1, cIAP2, and Mcl1 was analysed (e) by real-time PCR or (f) by western blotting using tubulin as control. In panels (b) and (e), data represent the mean ± s.d., n ¼ 3.
colon mucosa from dextran sulfate sodium-induced colitis in mice Osburn et al., 2007) and, consequently, Nrf2 deficiency leads to a more severe inflammation and tissue damage, giving rise to cancer. Although these findings indicate an antitumor protective activity of Nrf2 that underlies new concepts of chemopreventive measures (Osburn and Kensler, 2008) -that is, by administration of sulphoraphanethe constitutive Nrf2 activation may be 'highjacked' by the tumor cells later on, thereby providing survival and growth advantages (Osburn and Kensler, 2008) . In the latter condition, Nrf2-dependent proteasome activation might be essentially involved. This is supported by the observation that the overexpression or induction of Nrf2 in NCM460 cells confers protection against TRAIL-induced apoptosis, an effect not seen if S5a or a-5 expression was knocked down. Intriguingly, the protecting effect by Nrf2 involves an enhanced NF-kB activation by TRAIL, giving rise to a stronger expression of antiapoptotic target genes. Moreover, a close relation of enhanced Nrf2 activation and higher NF-kB activity was detectable in a line of tissue samples from colon cancer patients (Supplementary Figure 2) . Thus, even though inhibitory interferences between Nrf2 and NF-kB have also been reported (Liu et al., 2008; Song et al., 2009) , our findings point to a stimulatory interference reflecting a complex crosstalk of these transcription factors in carcinogenesis (Nair et al., 2008) .
Beside persisting oxidative and electrophilic stress in the tumoral environment resulting from inflammatory processes, an enhanced metabolism or the depletion of iron, certain mutations or altered DNA methylation patterns affecting the Keap1-Nrf2 pathway similarly contribute to the constitutive activation of Nrf2 (Singh et al., 2006; Nioi and Nguyen, 2007; Shibata et al., 2008a; Hayes and McMahon, 2009 ). In various tumor entities, Keap-1 mutations have been detected, accounting for Nrf2-dependent protection from anticancer drug toxicity and tumorigenesis (Nioi and Nguyen, 2007; Yamamoto et al., 2008; Shibata et al., 2008a) . Even mutations in Nrf2 itself are under suspect (Hayes and McMahon, 2009; Shibata et al., 2008b) . With respect to its important role in the control of the 26S-Pr, it now emerges that the constitutive activation of Nrf2 provides another growth advantage to tumor cells, in addition to the Nrf2-dependent resistance to anticancer drugs (Lau et al., 2008) . Thus, the increased proteasomal activity resulting from Nrf2 activation might lead to profound protection from apoptosis, an accelerated cell growth and an increased removal of potentially harmful proteins. Deregulation of Nrf2 activation-that is, due to Keap1 deficiency-along with the induction of proteasomal gene expression may also compensate for the antitumor effects of proteasome inhibitors, thereby accounting for the failure of these agents in the treatment of certain types of cancer.
In summary, our findings indicate that Nrf2 activity is elevated in colon cancer, accounting for the overexpression of proteasome subunit proteins and, thereby, for an increased proteasome activity. As the gain of proteasome activity accompanies malignant transformation of tumor cells, Nrf2 in this way might contribute to tumorigenesis. Moreover, the role of Nrf2 in cancer prevention has to be critically considered, because the pharmacological induction of Nrf2 (that is, by antioxidants) might be advantageous (preventive) at an early state of tumorigenesis, whereas this would be deleterious at a later stage of tumorigenesis (Lau et al., 2008) .
Materials and methods

Cell lines and culture
The Colo320 and LoVo cells (DSMZ, Braunschweig) were cultured in RPMI-1640 (PAA, Co¨lbe, Germany) containing 1% glutamine (Invitrogen/GIBCO, Karlsruhe, Germany) and 10% fetal calf serum (Biochrom, Berlin, Germany). Human NCM460 colonocytes (Moyer et al., 1996) were provided by INCELL Corp. (San Anatonio, TX, USA) and cultured in M3A medium (INCELL) containing 10% fetal calf serum. The cells were cultured at 37 1C in 5% CO 2 and at 85% humidity.
Tumor sample preparation Tissue samples were collected from colorectal cancer patients. The study was approved (A110/99) by the local ethics committee, and informed consent was obtained according to the Declaration of Helsinki. Frozen tissue specimens were homogenized (30 s, 15 000 r.p.m.) using the cryogenic ball mill MM400 (Retsch, Haan, Germany) and resuspended in the indicated buffers for N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosyl-7-amido-4-methylcumarin assay, western blot or gel shift assay (see below and in the Supplementary information).
Fluorometric proteasome assay
For the determination of proteasomal activity in living cells and tissue extracts, a fluorometric assay using the proteasome substrate, N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosyl-7-amido-4-methylcumarin, was performed as described in the Supplementary information.
Western blotting
The preparation of samples, electrophoresis and immunoblotting is specified in the Supplementary information.
Gel shift assay
Gel shift assays were conducted as described (Arlt et al., 2003) using the g-32 P-labeled consensus antioxidant response elementoligonucleotide 5 0 -CGCAGTCACAGTGACTCAGCAGAAT CTGAG-3 0 (Kepa and Ross, 2003) , or a consensus NF-kBoligonucleotide (Promega, Mannheim, Germany). NF-kB supershifts were performed as described (Arlt et al., 2003) .
Immunohistochemistry
Consecutive cryostat sections (6 mm) were mounted on uncovered glass slides, air-dried overnight at room temperature, fixed in chilled acetone (Merck, Darmstadt, Germany) for 10 min and air-dried again for 10 min. Then, slides were washed in phosphate buffered saline. To avoid nonspecific binding, sections were treated with 4% bovine serum albumine (Serva, Heidelberg, Germany) for 20 min, followed by incubation with the primary antibody (Abcam, Cambridge, UK). For detection of Nrf2, a monoclonal rabbit antibody, and for Nrf2 and proteasomal activation in colorectal cancer A Arlt et al detection of S5a and CK20, monoclonal mouse antibodies were used at 1:100 dilutions in 1% bovine serum albumine/ phosphate buffered saline. After primary antibody incubation (overnight, 4 1C), sections were washed three times in phosphate buffered saline and then treated with EnVision peroxidase conjugates (Dako, Hamburg, Germany) for 30 min. Afterward, sections were washed three times in phosphate buffered saline. Then, peroxidase substrate reaction was performed using the DAB peroxidase substrate kit (Vector Laboratories, Peterborough, UK) according to the manufacturer's instructions. Afterward, sections were washed in water, counterstained in 50% haemalaun (Merck) and mounted with glycerol-gelatin. The same protocol was performed for negative controls, either omitting the first antibody or using an isotype-matched control antibody.
RNA preparation and real-time PCR Isolation of total RNA and reverse-transcription into singlestranded complementary cDNA was carried out as described (Arlt et al., 2007) . The complementary DNA was subjected to real-time PCR (iCycler; Bio-Rad) using the SYBR-Green assay with gene-specific primers at a final concentration of 0.2 mM. The primer sequences and PCR conditions are provided in the Supplementary information.
Complementary DNA transfection and small interfering (si) RNA treatment The cells were subjected to lipofection using Effectene (Qiagen, Hilden, Germany) and either 0.8 mg pMH-Nrf2-HA (kind gift from P Nioi, Schering-Plough Research Institute, NJ, USA) or the empty vector. After 16 h, medium was changed and culture continued for 8-24 h until further treatment. Gene silencing was performed using the HiperFect reagent (Qiagen) and 150 ng/well of either negative control siRNA (Qiagen) or Nrf2 (SI03246614, Qiagen), S5a (SI03019331, Qiagen) or a-5 siRNA (SI100043316, Qiagen). After 8 h, medium was changed and cells were cultured for 48 h until further treatment.
Caspase-3/7 and annexinV/propidium iodide assay Apoptosis induced by killer-TRAIL (Axxora/Alexis, Gru¨nberg, Germany) was determined by staining cells with annexinV/ propidium iodide (BD-Biosciences, Heidelberg, Germany) or by measurement of caspase-3/-7 activity (Promega), both according to the manufacturer's instructions and as described (Sebens Mu¨erko¨ster et al., 2008) . All assays were performed in duplicates.
Statistics
Data represent the mean±s.d. and were analysed by Student's t-test or by Pearson correlation. A P-value o0.05 was considered as statistically significant.
Abbreviations
LLVY-AMC, N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosyl-7-amido-4-methylcumarin; Nrf2, nuclear factor E2-related factor-2; tBHQ, tert-butyl-hydroquinone; UPP, ubiquitinproteasome pathway; 26S-Pr, 26S-proteasome; 20S-CP, 20S catalytical particle; 19S-RP, 19S regulatory particle.
